Showing results (141-150 of 426) with videos related to
Sort By:
Pageof 43
Current Pharmaceutical Design|November 25, 2005
Heterogeneity of synthetic factor Xa inhibitorsGrigoris T Gerotziafas, Meyer M SamamaSeminars in Thrombosis and Hemostasis|September 30, 2000
Comparative pharmacokinetics of LMWHsM M Samama, G T GerotziafasSeminars in Thrombosis and Hemostasis|June 5, 1999
Laboratory diagnosis of the thrombophilic state in cancer patientsI Gouin-Thibault, M M SamamaVutreshni Bolesti|January 1, 1976
[Quantitative determination of Willebrand factor activity in Willebrand's disease]V Buchvarova, M Samama, C LecrubierArchives Des Maladies Du Coeur Et Des Vaisseaux|November 1, 1991
[Heparin in the treatment and secondary prevention of myocardial infarction. A critical review of the main trials]A Kher, M Samama, R HaïatArchives Des Maladies Du Coeur Et Des Vaisseaux|November 1, 1991
[Therapeutic indications of low molecular weight heparins]M M Samama, F Michaut-PaternoPathologie-Biologie|June 1, 1989
[Dermatan sulfate and the prevention of experimental venous thrombosis]P Desnoyers, L Bara, M SamamaArchives Des Maladies Du Coeur Et Des Vaisseaux|May 1, 1988
[Actilyse: biological aspects]M Samama, B Cormier, J ConardThrombosis Research|February 15, 1990
In vitro effect on Heptest of low molecular weight heparin fractions and preparations with various anti-IIa and anti-Xa activitiesL Bara, J Mardiguian, M SamamaPageof 43